# AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer

> **NCT00089661** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 252 (actual)

## Conditions studied

- Breast Cancer
- Low Bone Mineral Density
- Osteopenia

## Interventions

- **DRUG:** Placebo
- **DRUG:** AMG 162 / Denosumab

## Key facts

- **NCT ID:** NCT00089661
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10-01
- **Primary completion:** 2007-05-11
- **Final completion:** 2009-05-27
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2018-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00089661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00089661, "AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00089661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*